CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 108 enrolled
Drug / intervention
Radiopaque Implanon +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00620464
NCT00620464Phase 3Completed
CompareCT.gov

A Randomized, Double-Blind, Parallel Group, Bioequivalence Study of IMPLANON and Radiopaque IMPLANON

Organon and Co·interventional·Posted Feb 21, 2008·Updated Feb 4, 2022

In Brief

A Phase 3 clinical trial evaluating Radiopaque Implanon and Implanon (etonogestrel implant) for Contraception. Completed, enrolled 108 participants.

Detailed Summary

The primary purpose of this study is to demonstrate the bioequivalence of IMPLANON and Radiopaque IMPLANON.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContraception
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 21, 2008
Enrollment StartMay 1, 2005
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 18.4 years ago

Interventions

Radiopaque Implanondrug

Radiopaque rod for 3 years

Implanon (etonogestrel implant)drug

Implanon (etonogestrel implant) for 3 years